Pliant Therapeutics annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Pliant Therapeutics R&D Spending Growth & History (PLRX)
Pliant Therapeutics's r&d spending was $109.2M for fiscal 2025.
View full Pliant Therapeutics company overviewPliant Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $109.2M | −$60.2M | −35.53% |
| 2024 | 2024-12-31 | $169.3M | $41.5M | +32.48% |
| 2023 | 2023-12-31 | $127.8M | $30.9M | +31.84% |
| 2022 | 2022-12-31 | $96.9M | $19.4M | +25.00% |
| 2021 | 2021-12-31 | $77.5M | $11.4M | +17.16% |
| 2020 | 2020-12-31 | $66.2M | $18.8M | +39.79% |
| 2019 | 2019-12-31 | $47.4M | — | — |
Pliant Therapeutics quarterly r&d spending
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $16.7M | −$15.5M | −48.05% |
| Q1 2026 | 2026-03-31 | $13.6M | −$29.9M | −68.73% |
| Q4 2025 | 2025-12-31 | $15.6M | −$23.2M | −59.83% |
| Q3 2025 | 2025-09-30 | $17.9M | −$29.8M | −62.44% |
| Q2 2025 | 2025-06-30 | $32.2M | −$13.4M | −29.42% |
| Q1 2025 | 2025-03-31 | $43.4M | $6.3M | +16.93% |
| Q4 2024 | 2024-12-31 | $38.8M | $5.6M | +16.91% |
| Q3 2024 | 2024-09-30 | $47.8M | $15.4M | +47.67% |
| Q2 2024 | 2024-06-30 | $45.6M | $12.6M | +38.22% |
| Q1 2024 | 2024-03-31 | $37.1M | $7.9M | +26.90% |
| Q4 2023 | 2023-12-31 | $33.2M | $8.1M | +32.13% |
| Q3 2023 | 2023-09-30 | $32.3M | $7.7M | +31.43% |
| Q2 2023 | 2023-06-30 | $33.0M | $6.7M | +25.32% |
| Q1 2023 | 2023-03-31 | $29.3M | $8.4M | +40.19% |
| Q4 2022 | 2022-12-31 | $25.1M | $6.4M | +33.93% |
| Q3 2022 | 2022-09-30 | $24.6M | $3.6M | +16.88% |
| Q2 2022 | 2022-06-30 | $26.3M | $7.1M | +37.03% |
| Q1 2022 | 2022-03-31 | $20.9M | $2.4M | +12.71% |
| Q4 2021 | 2021-12-31 | $18.8M | $898,000 | +5.03% |
| Q3 2021 | 2021-09-30 | $21.1M | $4.2M | +24.69% |
| Q2 2021 | 2021-06-30 | $19.2M | $1.7M | +9.59% |
| Q1 2021 | 2021-03-31 | $18.5M | $4.6M | +33.11% |
| Q4 2020 | 2020-12-31 | $17.9M | — | — |
| Q3 2020 | 2020-09-30 | $16.9M | $6.1M | +56.64% |
| Q2 2020 | 2020-06-30 | $17.5M | $4.4M | +33.88% |
| Q1 2020 | 2020-03-31 | $13.9M | — | — |
| Q3 2019 | 2019-09-30 | $10.8M | — | — |
| Q2 2019 | 2019-06-30 | $13.1M | — | — |
Pliant Therapeutics r&d spending trends
Over the last five fiscal years, Pliant Therapeutics's r&d spending increased from $66.2M to $109.2M, a change of $43.0M. The latest reported quarter, Q2 2026, shows $16.7M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pliant Therapeutics source filings ↗